BUSINESS ACQUISITION - Narrative (Details) - USD ($) $ in Thousands				1 Months Ended	3 Months Ended			9 Months Ended
	May 25, 2017	Apr. 04, 2017	Feb. 24, 2017	Aug. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Business Acquisition [Line Items]
Realized loss on sale of short-term investment						$ 2,300		$ 2,287	$ 0
Payment for contingent consideration								4,661	0
Change in fair value of contingent consideration								(2,773)	81
Net income					$ 3,159		$ 20,144	20,388	$ 46,316
Interest Expense, Intangible Asset Amortization, and External Expenses Related to Acquisition
Business Acquisition [Line Items]
Net income								$ 12,500
Product Concentration Risk | BioD Morselized Amniotic Membrane Based Products
Business Acquisition [Line Items]
Percentage of revenue to product (less than)					1.00%			1.00%
Derma Sciences | Interest Expense, Intangible Asset Amortization, and External Expenses Related to Acquisition
Business Acquisition [Line Items]
Net income								$ 2,900
TGX Medical
Business Acquisition [Line Items]
Consideration for acquisition		$ 5,400
Revenue of acquired company since acquisition					$ 200			400
TGX Medical | TGX Medical
Business Acquisition [Line Items]
Additional closing costs incurred					100
Derma Sciences
Business Acquisition [Line Items]
Consideration for acquisition			$ 210,800
Revenue of acquired company since acquisition					24,100			58,400
Payment of closing expenses			4,800
Settlement of stock compensation plan			4,300
Cash payment to former shareholders			$ 201,700
Preliminary purchase price allocation adjustment						1,700
Goodwill purchase price adjustment, cash received from escrow					300
Acquired deferred taxes					17,865			17,865
Deferred tax asset, federal net operating loss					39,700			39,700
Deferred tax asset, intangibles					15,800			15,800
Deferred tax asset, various					700			700
Deferred tax liabilities, intangibles					38,300			38,300
Deferred tax liabilities, adjustment to estimated fair value					1,500			1,500
Derma Sciences | BioD Earnout Payments
Business Acquisition [Line Items]
Revenue volatility percentage			13.50%
Fair value inputs, discount rate			3.00%
Contingent consideration maximum payout			$ 26,500
Estimated fair value of the remaining portion of the contingent consideration, liability			$ 9,100		2,100			2,100
Payment for contingent consideration				$ 4,800
Derma Sciences | Product Payment Contingent Consideration
Business Acquisition [Line Items]
Fair value inputs, discount rate			2.50%
Contingent consideration maximum payout			$ 29,700
Estimated fair value of the remaining portion of the contingent consideration, liability			$ 26,800
Product payment rate			98.00%
Change in fair value of contingent consideration						$ 900
Payment for the product payment	$ 26,600
Derma Sciences | Medihoney Earnout Payments
Business Acquisition [Line Items]
Revenue volatility percentage			27.50%
Fair value inputs, discount rate			4.50%
Contingent consideration maximum payout			$ 5,000
Estimated fair value of the remaining portion of the contingent consideration, liability			$ 1,400		$ 1,400			$ 1,400